Loading...
XNYS
TFX
Market cap5.93bUSD
Jul 09, Last price  
134.04USD
1D
2.83%
1Q
13.22%
Jan 2017
-16.82%
Name

Teleflex Inc

Chart & Performance

D1W1MN
XNYS:TFX chart
P/E
P/S
2.98
EPS
Div Yield, %
1.01%
Shrs. gr., 5y
-1.11%
Rev. gr., 5y
-4.72%
Revenues
1.99b
-34.61%
2,646,757,0001,934,332,0002,420,949,0001,890,062,0001,801,705,0001,528,911,0001,551,009,0001,696,271,0001,839,832,0001,809,690,0001,868,027,0002,146,303,0002,448,383,0002,595,362,0002,537,156,0002,809,563,0002,791,041,0002,974,489,0003,047,324,0001,992,713,000
Net income
-906m
L
139,430,000146,484,000119,774,000302,994,000201,094,000323,329,000-190,057,000150,881,000187,679,000244,863,000237,377,000152,530,000200,802,000461,466,000335,324,000485,374,000363,139,000356,328,00069,675,000-905,640,000
CFO
341m
-46.41%
344,662,000393,588,000171,169,000204,171,000213,102,00094,478,000186,054,000226,544,000286,565,000300,810,000408,480,000419,885,000437,378,000439,525,000436,406,000651,419,000342,141,000510,638,000635,739,000340,677,000
Dividend
Nov 14, 20250.34 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
IPO date
Mar 17, 1980
Employees
15,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT